Hepatic insulin extraction (None established; sometimes referred to as "HIE" in research contexts, but not a widely accepted abbreviation.)

Hepatic insulin extraction refers to the physiological process by which the liver removes circulating endogenous or exogenous insulin from portal blood following its secretion from pancreatic β-cells. This occurs primarily through binding of circulating insulin to hepatocyte surface insulin receptors, followed by internalization/endocytosis and subsequent degradation within hepatocytes—mechanisms involving proteins like CEACAM1 and possibly IDE[1][2]. Under normal conditions, up to ~80% of secreted endogenous human insulin is cleared during its first pass through the liver before reaching systemic circulation. This regulatory step plays an essential role in maintaining appropriate systemic concentrations of active hormone available for action at extrahepatic tissues including muscle and adipose tissue. Impairment in this pathway contributes significantly to metabolic diseases such as type 2 diabetes mellitus—where reduced clearance leads both to compensatory hypersecretion from β-cells ("hyperinsulinemia") and increased risk for fatty liver disease due to excess intrahepatic lipid synthesis driven by high local concentrations of active hormone[1][3]. In summary, while critical for metabolic regulation—and often discussed in pathophysiology—"hepatic insulin extraction" does not represent an individual druggable target but rather describes an integrated physiological function involving several molecular players within hepatocytes.[1][2]

Other names

Hepatic insulin clearanceLiver insulin extractionFirst-pass hepatic insulin clearance

Not applicable for this process itself. For related molecules: Insulin binds to its hepatocyte surface receptors; subsequent endocytosis and degradation regulate plasma levels. Some mechanisms involve modulation of the insulin-insulin receptor complex, CEACAM1-mediated endocytosis, and lysosomal degradation pathways in hepatocytes.